Ethics The WCGTM Institutional Review Board approved the procedures used in the study, and there was full compliance with human experimentation guidelines. All participants provided written informed consent before study participation.
DATA AVAILABILITY
The data are available to members of the Critical Path for Parkinson’s Consortium 3DT Initiative Stage 2. For those who are not a part of 3DT Stage 2, a proposal may be made to the WATCH-PD Steering Committee (via the corresponding author) for deidentified baseline datasets.
CODE AVAILABILITY
Pseudocode is available within the supplementary materials. Additional code is available from the authors upon request.
ACKNOWLEDGEMENTS
Funding for the study was contributed by Biogen, Takeda, and the members of the Critical Path for Parkinson’s Consortium 3DT Initiative, Stage 2.
AUTHOR CONTRIBUTIONS
Conception and paper drafting: M.D.C, J.C. Data processing and statistical analysis: M.D.C, D.B. Interpretation of data and critical revision of the manuscript: All authors.
COMPETING INTEREST DECLARATION
Dr. Czech, Dr. Yang, Dr. Shen, Dr. Crouthamel, and Dr. Cosman are employees of and own stock in AbbVie Pharmaceuticals. Dr. Adams has received compensation for consulting services from VisualDx and the Huntington Study Group; and research support from Biogen, Biosensics, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health/National Institute of Neurological Disorders and Stroke, NeuroNext Network, and Safra Foundation. Ms. Tairmae Kangarloo is an employee of and owns stock in Takeda Pharmaceuticals, Inc. Mr. Darryl Badley was an employee of AbbVie Pharmaceuticals during the time he contributed to this research article. He has no conflicts or interests at the present time. Dr. Dorsey has received compensation for consulting services from Abbott, Abbvie, Acadia, Acorda, Bial-Biotech Investments, Inc., Biogen, Boehringer Ingelheim, California Pacific Medical Center, Caraway Therapeutics, Curasen Therapeutics, Denali Therapeutics, Eli Lilly, Genentech/Roche, Grand Rounds, Huntington Study Group, Informa Pharma Consulting, Karger Publications, LifeSciences Consultants, MCM Education, Mediflix, Medopad, Medrhythms, Merck, Michael J. Fox Foundation, NACCME, Neurocrine, NeuroDerm, NIH, Novartis, Origent Data Sciences, Otsuka, Physician’s Education Resource, Praxis, PRIME Education, Roach, Brown, McCarthy & Gruber, Sanofi, Seminal Healthcare, Spark, Springer Healthcare, Sunovion Pharma, Theravance, Voyager and WebMD; research support from Biosensics, Burroughs Wellcome Fund, CuraSen, Greater Rochester Health Foundation, Huntington Study Group, Michael J. Fox Foundation, National Institutes of Health, Patient-Centered Outcomes Research Institute, Pfizer, PhotoPharmics, Safra Foundation, and Wave Life Sciences; editorial services for Karger Publications; stock in Included Health and in Mediflix, and ownership interests in SemCap.
ADDITIONAL INFORMATION
Supplementary information is available for this paper.
Correspondence and requests for materials should be addressed to Matthew D. Czech.
Reprints and permission information is available at http://www.nature.com/reprints